NCT07014917View on ClinicalTrials.gov

Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

June 1, 2028

Study Completion Date

June 1, 2032

Conditions
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaCLL Variant
Interventions
DRUG

Venetoclax

intermittent venetoclax (7days administration per cycle) + acalabrutinib

DRUG

Acalabrutinib

intermittent venetoclax (7days administration per cycle) + acalabrutinib

DRUG

Venetoclax

continuous venetoclax (28 days administrations per cycle) + acalabrutinib

DRUG

Acalabrutinib

continuous venetoclax (28 days administrations per cycle) + acalabrutinib

Trial Locations (1)

45219

University of Cincinnati, Cincinnati

All Listed Sponsors
lead

Zulfa Omer

OTHER